@article{30dd2c3a7d3a4890b43e2e85ec6833e3,
title = "American ginseng does not improve fatigue in multiple sclerosis: A single center randomized double-blind placebo-controlled crossover pilot study",
abstract = "This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.",
keywords = "Panax, clinical trial, complementary therapies, fatigue, ginseng, multiple sclerosis",
author = "E. Kim and M. Cameron and J. Lovera and L. Schaben and D. Bourdette and R. Whitham",
note = "Funding Information: This study was supported by National MS Society grants PP1307 (Pilot Project Award) and CA 1055-A-3 (Collaborative MS Research Center Award); PHS Grant 5 M01 RR000334; the Medical Research Foundation; and the Nancy Davis Center without Walls. This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Funding Information: Dr Kim and Dr Schaben were Multiple Sclerosis Fellows supported by the Department of Veterans Affairs. Dr Cameron was supported by a Career Development Award from the Department of Veterans Affairs, Rehabilitation Research and Development Service. Ginseng and placebo products were donated by Afexa Life Sciences Inc. (Edmonton, Canada). ",
year = "2011",
month = dec,
doi = "10.1177/1352458511412062",
language = "English (US)",
volume = "17",
pages = "1523--1526",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "12",
}